NCT05970978View on ClinicalTrials.gov

A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With Biologics

PHASE2CompletedINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

August 28, 2023

Primary Completion Date

July 19, 2024

Study Completion Date

January 26, 2025

Conditions
Psoriasis
Interventions
DRUG

regular treatment

IBI112 200mg s.c. at week 0, 12, 24 and 36.

DRUG

Intensive treatment

IBI112 200mg s.c. at week 0, 4, 8, 20 and 32.

Trial Locations (1)

250000

Dermatology Hospital of Shandong First Medical University (Shandong Provincial Hospitial of Dermatology), Jinan

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT05970978 - A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With Biologics | Biotech Hunter | Biotech Hunter